Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 20Lung Neoplasms 18Glioma 13Neoplasm Metastasis 11Carcinoma, Non-Small-Cell Lung 11Breast Neoplasms 11Urinary Bladder Neoplasms 10Pancreatic Neoplasms 10Multiple Myeloma 10Lymphoma 10Squamous Cell Carcinoma of Head and Neck 9Mouth Neoplasms 9Colorectal Neoplasms 8Carcinoma, Renal Cell 8Ovarian Neoplasms 7Oropharyngeal Neoplasms 7Melanoma 7Laryngeal Neoplasms 7Glioblastoma 7Carcinoma, Hepatocellular 7Carcinoma 7Wilms Tumor 6Sarcoma 6Neuroblastoma 6Nasopharyngeal Carcinoma 6Medulloblastoma 6Lymphoma, Non-Hodgkin 6Fallopian Tube Neoplasms 6Triple Negative Breast Neoplasms 5Rhabdoid Tumor 5

Interventions

relugolix 1enzalutamide 1Specimen Handling 1Radiotherapy, Image-Guided 1Radiotherapy 1Radiation Dose Hypofractionation 1Radiation 1Magnetic Resonance Spectroscopy 1Biopsy 12-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Prostate Adenocarcinoma × Magnetic Resonance Spectroscopy × 30 days × Clear all
NCT06499870 2026-06-05

Relugolix and Enzalutamide in Combination With Radiation Therapy for the Treatment of Very High Risk Prostate Cancer, OPTIMAL Trial

Northwestern University

Phase 2 Recruiting
50 enrolled
Genitourinary

Prostate Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡